Agios Pharmaceuticals (NASDAQ:AGIO) said it will receive $1.1 billion in milestone payments following the FDA’s approval of vorasidenib for the treatment of malignant brain tumors.

The biotech company said it will receive $905 million from Royalty Pharma in connection with a recent royalty agreement agreement and $200 million from Servier, which acquired vorasidenib in 2021 when it bought Agios’ oncology business, according to the statement.

Earlier on Tuesday, The FDA announced approved vorasidenib for the treatment of patients 12 years of age and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation, following surgery involving biopsy, partial resection, or gross complete resection.

The treatment will be marketed by Servier under the brand name Voranigo.

Agios said the payments, expected in the third quarter, will boost its cash position to $1.7 billion. The additional cash will allow the company to prepare for potential launches of Pyrukynd, also known as mitapivat, for thalassemia in 2025 and sickle cell disease in 2026.